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ABSTRACT: The Zika virus presents a major public health concern due to severe fetal neurological disorders associated 
with infections in pregnant women. In addition to vaccine development, the discovery of selective antiviral drugs is essential 
to combat future epidemic Zika virus outbreaks. The Zika virus NS2B-NS3 protease, which performs replication-critical 
cleavages of the viral polyprotein, is a promising drug target. We report the first macrocyclic peptide-based inhibitors of 
the NS2B-NS3 protease, discovered de novo through in vitro display screening of a genetically reprogrammed library includ-
ing non-canonical residues. Six compounds were selected, re-synthesized and isolated, all of which displayed affinities in 
the low nanomolar concentration range. Five compounds showed significant protease inhibition. Two of these were vali-
dated as hits with sub-micromolar inhibition constants and selectivity toward Zika over the related proteases from dengue 
and West Nile viruses. The compounds were characterized as non-competitive inhibitors, suggesting allosteric inhibition.                    
In recent years, the Zika virus has emerged from a ne-
glected member of the flavivirus genus to a health-threat-
ening pathogen.1 Although most infections are asympto-
matic, neurological complications such as the Guillain-
Barré syndrome have been reported in a small proportion 
of patients. The link between severe disorders in fetuses 
(microcephaly) and Zika virus infections in pregnant 
woman prompted the WHO to declare Zika virus a Public 
Health Emergency of International Concern in 2016.1, 2 
Since then, the virus has circulated in almost all Caribbean 
and Latin American countries, continental USA (e.g. Flor-
ida and Texas), Africa, Southeast Asia, and several Pacific 
islands with infections reported in 84 countries and terri-
tories around the globe. In contrast to other prominent ex-
amples of flaviviruses, such as dengue or West Nile, the 
Zika virus can be transmitted not only by Aedes aegypti and 
Aedes albopictus mosquitos, but also through sexual con-
tact.1, 2 About 30 potential Zika virus vaccines are currently 
being evaluated, out of which only four have entered phase 
1 clinical trials.2 Particularly concerning for Zika (and den-
gue) virus vaccination campaigns are potential cross-reac-
tions between Zika and dengue virus antibodies, where the 
resulting antibody-dependent enhancements can lead to 
increased viremia and severity of the disease, as observed 
previously for consecutive infections with different dengue 
virus serotypes.2 Therefore, alternative specific antiviral 
therapeutic options are needed for the treatment of symp-
tomatic patients and infected pregnant women. 
Like other flaviviruses, Zika virus comprises a single-
stranded positive sense RNA genome that encodes a viral 
polyprotein, which is post-translationally processed by 
host-cell proteases and the viral NS2B-NS3 protease into 
three structural (C, prM/M, E) and seven non-structural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The 
NS2B-NS3 protease of flaviviruses is considered a promis-
ing antiviral drug target and several lead compounds have 
already been discovered for the corresponding dengue vi-
rus proteases.3 NS2B-NS3 is a serine protease, which con-
sists of the N-terminal domain of NS3 and a short cofactor 
from the hydrophilic core sequence of NS2B. For in vitro 
screening campaigns, three different Zika virus NS2B-NS3 
protease (ZIKVpro) constructs have been proposed and 
crystallized. First, a construct with a covalent linker pep-
tide between NS2B and NS3 (gZiPro) was adopted based on 
previous successful dengue and West Nile virus protease 
constructs.4 Two additional unlinked versions have been 
described, which are based on either NS2B/NS3 co-expres-
sion (bZiPro)5 or an autocleavage site in the linker peptide 
between NS2B and NS3 (eZiPro).6 The C-terminal 
tetrapeptide of NS2B in eZiPro was shown to interfere with 
access of substrate to the active site.6 
Few ZIKVpro inhibitors have been described so far.7 The 
most effective ones are substrate-derived peptide analogs 
that bind covalently to the catalytically active serine resi-
due (e.g. cn-716, Figure 2).4, 8, 9 However, due to conserved 
features in substrate recognition amongst serine proteases, 
 
these compounds display only poor selectivity between fla-
viviral and host proteases.8 Therefore, alternative non-ac-
tive-site inhibitors that do not mimic the substrate or tran-
sition state may exhibit decreased off-target effects. Re-
cently, natural products as well as compounds derived 
from previous West Nile virus screening campaigns have 
been reported to act as micromolar allosteric inhibitors of 
ZIKVpro.10, 11 In view of the limited coverage of chemical 
space offered by natural products and compound libraries, 
as well as common bias for promiscuous binders, we set 
out to identify completely new structural scaffolds de novo 
by capitalizing on recent advances in mRNA display tech-
niques.                                 . 
 
Figure 1. Design of macrocyclic peptide libraries for screening. The peptide libraries for screening were synthesized by ge-
netically reprogrammed translation of a new mRNA library that was more focussed on hydrophobic residues than previous librar-
ies. The codon table for the genetic code used is shown in (A) with Met replaced with N-chloroacetyl-tyrosine (ClAc-Y) for the 
initiation AUG codon or N-methyl-leucine (MeL) for all downstream AUG codons. B: Structures of the non-canonical amino acids 
used. C: The peptide libraries were synthesized by translation of a semi-random mRNA template comprised of an AUG start codon, 
8-10 NNS codons (N = A, G, C or U; S = G or C), a UGC (Cys) codon, and a linker sequence for covalent linkage of each peptide and 
mRNA. Translation of this library under the genetic code shown leads to formation of a semi-randomized peptide library that 
cyclizes spontaneously to produce a macrocyclic peptide library. * Two libraries were synthesized, one initiated with ClAc-L-Y and 
one initiated with ClAc-D-Y. 
Small (< 2 kDa) macrocyclic peptides are appealing start-
ing points for such drug discovery. A key strength of mac-
rocyclic peptides is that high-affinity ligands can be iso-
lated for nearly any target rapidly using display screening 
approaches (phage display, mRNA display, etc.).12 Moreo-
ver, display screening can be combined with genetic code 
reprogramming techniques, allowing the screening of li-
braries incorporating structural characteristics such as 
backbone N-methylation and/or D-stereochemistry, which 
have been shown to improve biostability and membrane 
permeability, and therefore making the resulting hit com-
pounds better starting points for drug discovery efforts 
than canonical peptides.12-14 In the present study, we have 
used such a screening approach (Random non-standard 
Peptide Integrated Discovery, RaPID – Figure S1) to iden-
tify potent macrocyclic peptide ligands of ZIKVpro. These 
peptide ligands were specific non-competitive inhibitors 
for ZIKVpro, and several were found to display sub-mi-
cromolar inhibition constants (Ki). This study highlights 
the ability of such screening approaches to rapidly identify 
potent inhibitors of newly discovered targets such as those 
from emerging viral diseases. 
In order to identify novel inhibitors of ZIKVpro, we de-
signed two macrocyclic peptide libraries for affinity screen-
ing by RaPID display. The libraries were constructed using 
a genetically reprogrammed in vitro translation approach 
and were designed to include five N-methyl residues (MeG, 
MeL, MeA, MeS, MeF) and the unnatural amino acid N-methyl-
4-O-methyl-tyrosine (MeYMe) (Figure 1, A and B). Each li-
brary was initiated with either L- or D-N-chloroacetyl tyro-
sine, in order to induce spontaneous macrocyclization fol-
lowing translation (Figure 1C).15 The genetic code was de-
signed such that the non-canonical amino acids replaced 
Met (allowing for reprogramming of translation initiation) 
and all of the canonical residues except Lys which have 
charged side chains at neutral pH (i.e. Asp, Glu, and Arg). 
Additionally, the random region of the peptide library was 
limited to a maximum of 10 codons, making the overall li-
brary both less charged and smaller than any previously re-
ported comparable cyclic peptide libraries.12, 13, 16-21 The total 
theoretical diversity of both libraries combined exceeded 
5 · 1013 macrocyclic peptides, making the total number of 
compounds screened several orders of magnitude greater 
than is typical using conventional high-throughput meth-
ods.  
Iterative affinity screening of these libraries against the 
linked ZIKVpro construct (gZiPro) immobilized on mag-
netic beads led to the identification of six families of mac-
rocyclic peptide ligands (alignments of the 100 most fre-
quent sequences from each library are shown in Figure S2). 
The most abundant member of each of these was synthe-
sized by solid phase methodology omitting the C-terminal 
linker sequence (i.e. all residues C-terminal of the cyclizing 
 
cysteine). All six of these displayed high affinity for ZIK-
Vpro with dissociation constants (KD) in the range of 5 – 
168 nM as determined by surface plasmon resonance ex-
periments (Table 1, Table S1, Figure S4). All of these com-
pounds contain at least one unnatural modification in the 
peptide backbone and five out of six include the unnatural 
amino acid N-methyl-4-O-methyl-tyrosine (MeYMe), sug-
gesting that these features are crucial for high affinity. 
The selected compounds were further analyzed with re-
spect to their actual potential to inhibit the catalytic activ-
ity of the linked ZIKVpro construct (gZiPro) in a biochem-
ical assay. All compounds except 5 showed significant in-
hibition of ZIKVpro substrate processing below a 100 μM 
cutoff (Table 1, Figure S5). Notably, 5 is the only analyzed 
peptide macrocycle that lacks the unnatural O-methyl-ty-
rosine side chain. Despite having no influence on catalytic 
activity, compound 5 binds to ZIKVpro with extraordinary 
affinity (KD = 5 nM), indicating a tight binding event that 
is likely to be distant from the substrate binding site with-
out any impact on the structural integrity of the catalytic 
center. Therefore, compound 5 linked to any reporter mol-
ecules (e.g. via a C-terminal amide bond) might have ap-
plications in selective probing of ZIKVpro without perturb-
ing its activity. This exemplifies a major advantage of the 
presented affinity screening over conventional high-
throughput screening methods for protease inhibitors, 
which usually focus on inhibition only. 
  
Table 1. Affinity and inhibitory activity of macrocyclic peptides against flaviviral proteases. 
Cpd. Sequencea 




Ki / µMc  
(IC50 / µM) 
KD / µMd IC50 / µMe IC50 / µMf IC50 / µMg 
1 -S-Ac-YWKIMeYMeNTLVNIC-NH2 
0.80 ± 0.08 
(1.32 ± 0.03) 
0.02 1.5 ± 0.1 >10 >10 
2 -S-Ac-YMeYMeKMeFKMeSMeYMeKMeYMeMeYMeKC-NH2 
0.44 ± 0.03 
(0.62 ± 0.04) 
0.009 0.25 ± 0.01 1.7 ± 0.1 3.9 ± 0.4 
3 -S-Ac-YTNFYLYPYMeYMeFC-NH2 
2.0 ± 0.2 
(3.3 ± 0.2) 
0.008 2.2 ± 0.1 >20 >20 
4 -S-Ac-YMeGIAKYNMeYMeMeYMeIPC-NH2 
20.4 ± 2.3 
(16.5 ± 0.9) 
0.009 4.6 ± 0.3 ≥20 ≥20 
5 -S-Ac-YTLPFHNMeGTFFC-NH2 >100 0.005 ≥50 >20 >20 
6 -S-Ac-D-YAIIMeYMeYNKYMeLNC-NH2 
3.5 ± 0.4  
(7.1 ± 0.2) 
0.168 3.2 ± 0.4 >20 >20 
a The N-terminal thioether-acyl moiety (-S-Ac-) forms a macrocycle through the side chain of the underlined cysteine residue. 
MeYMe, N-methyl-4-O-methyl-tyrosine; MeF, N-methyl-phenylalanine; MeS, N-methyl-serine; MeG, N-methyl-glycine; MeL, N-methyl-
leucine; D-Y, D-tyrosine. b Zika virus NS2B-NS3 protease (linked construct) C80S/C143S (1 nM). Substrate: Bz-Nle-Arg-Lys-Lys-
AMC. c Inhibition constants (Ki) were calculated from measurements at four different substrate concentrations using a non-com-
petitive inhibition model (non-linear least-squares fits). Half maximal inhibitory concentrations (IC50) for a substrate concentra-
tion of 15 μM are reported in parenthesis. d Dissociation constants (KD) were determined by surface plasmon resonance using 
immobilized Zika virus NS2B-NS3 protease (gZiPro). e Zika virus NS2B-NS3 protease (unlinked construct; 0.5 nM). Substrate: Bz-
Nle-Arg-Lys-Lys-AMC. Half maximal inhibitory concentrations (IC50) were calculated for a substrate concentration of 15 μM. f 
Dengue virus serotype 2 NS2B-NS3 protease (100 nM). Substrate: Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr. Half maximal inhibitory 
concentrations (IC50) were calculated for a substrate concentration of 50 μM. g West Nile virus NS2B-NS3 protease (150 nM). 
Substrate: Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr. Half maximal inhibitory concentrations (IC50) were calculated for a substrate 
concentration of 50 μM. 
 
 
Figure 2. Chemical structures of synthesized hit compounds 1 and 2 that were identified as nanomolar non-competitive inhibitors 
of the Zika virus NS2B-NS3 protease. Compound cn-716 is a previously published4 covalent active-site inhibitor of the Zika virus 
NS2B-NS3 protease, which has been used in this study for comparison. 
To exclude any construct-specific artifacts, we further 
assessed the activity of the unlinked ZIKVpro construct 
(bZiPro) in the presence of compounds 1-6 using the same 
biochemical assay. The IC50 values observed for gZiPro and 
bZiPro were mostly similar (Table 1, Figure S6), indicating 
that the linked (gZiPro) and unlinked (bZiPro) constructs 
are equally suitable templates for drug discovery cam-
paigns. Compounds 1 and 2 displayed the strongest inhibi-
tion of ZIKVpro with inhibition constants firmly in the na-
nomolar range (Table 1). These two macrocyclic peptides 
are structurally unrelated (Figure 2) and may therefore 
serve as independent starting points for further optimiza-
tions. In contrast to the previously reported ZIKVpro ac-
tive-site inhibitor cn-716, which showed strong inhibition 
of thrombin (IC50 = 0.5 μM) and trypsin (IC50 = 0.05 μM),8 
neither compound 1 nor 2 displayed thrombin or trypsin 
inhibition at the highest assayed concentrations of 25 μM 
and 50 μM, respectively (data not shown), highlighting 
their specificity towards ZIKVpro.  
Mechanistic studies with gZiPro at various substrate and 
inhibitor concentrations revealed a non-competitive inhi-
bition mode for compounds 1–4 and 6, as evidenced both 
by non-linear least-squares data fits (Table S3) and Cor-
nish-Bowden plots. As an example, Figure 3A shows the 
Cornish-Bowden plot for the most active peptide 2, where 
the abscissa intersection point clearly indicates non-com-
petitive binding.22 As expected for the non-competitive 
binding model, the degree of inhibition was independent 
of the substrate concentration, even at multiples of the Km 
value. Due to the size of substrate and macrocyclic inhibi-
tor, both cannot occupy the active site simultaneously, 
suggesting that compounds 1–4 and 6 may act as allosteric 
antagonists of ZIKVpro activity. Allosteric inhibitors have 
been reported previously for dengue virus NS2B-NS3 pro-
teases at different sites of NS3,23, 24 which may also act by 
perturbing the essential interactions between NS2B and 
NS3.25 As expected for allosteric inhibitors, the Ki values 
were all greater than the KD values, suggesting inhibition 
by locking the protease in conformations less competent 
for catalysis (in the most extreme case, compound 5 binds 
with high affinity but does not affect the catalytic rate at 
all).  
 
Figure 3. A: Cornish-Bowden plot for compound 2 and Zika 
virus NS2B-NS3 protease (gZiPro). The intersection point (–
Ki) of the four independent linear fits with the abscissa indi-
cates a non-competitive inhibition mechanism with a Ki value 
of 0.44 μM.22 The same value was obtained from non-linear 
least-squares fits using a non-competitive binding model 
(Graphpad Prism 7.0; Table S3). B: Inhibition of Zika virus 
NS2B-NS3 protease (bZiPro) activity by the non-competitive 
inhibitor 2 and the covalently binding active-site inhibitor cn-
716. Addition of compound 2 in the presence of cn-716 results 
 
in synergistically decreased protease activity, suggesting that 
2 binds at an allosteric site. 
Although, in principle, resistance may easily evolve 
against allosteric inhibitors of viral proteases, such inhibi-
tors can be valuable therapeutics in combination with sub-
strate-derived active-site inhibitors. Established reverse 
transcriptase inhibitors for the treatment of chronic HIV 
infections are a prominent example.26 As drug-like active-
site inhibitors of flaviviral proteases suffer from low affin-
ity, their combination with allosteric antagonists is a 
promising route toward anti-flaviviral therapeutics with 
adequate pharmacokinetic properties. To support the po-
tential allosteric binding mode indicated by the non-com-
petitive inhibition data, we performed the activity assay 
with bZiPro in the presence and absence of compound 2 
and the covalent active-site inhibitor cn-716 (Figure 3B). 
As expected, the simultaneous presence of inhibitor 2 and 
cn-716 inhibited the ZIKVpro activity more strongly than 
the individual compounds at identical concentrations, in-
dicating synergistic inhibition of ZIKVpro (Figure 3B). As 
cn-716 is known to occupy the active site by binding cova-
lently to the active-site serine residue 135,4 this is strong 
evidence for compound 2 binding to a site distant from the 
substrate-binding site. Unfortunately, attempts to verify 
the allosteric binding mode by NMR spectroscopy or X-ray 
crystallography have failed to date because of the low sol-
ubility of the inhibitors. 
To further assess the specificity of the discovered inhib-
itors, we tested their performance with dengue and West 
Nile virus proteases (Table 1). Only compound 2 showed 
significant inhibition of both proteases in the low mi-
cromolar range with selectivity indices of 4 and 9 in favor 
of ZIKVpro over the dengue and West Nile virus proteases, 
respectively. Compounds 1 and 3 displayed selectivity indi-
ces greater than 10 in favor of ZIKVpro. Only compound 4 
showed similarly weak inhibition constants around 20 μM 
for all three viral proteases. The selectivity of our new in-
hibitors toward ZIKVpro is in stark contrast to the broad 
cross-reactivity of previously described flaviviral protease 
inhibitors, which are predominantly active-site inhibitors.7 
As the active center is highly conserved, selective targeting 
has been difficult in the past. Consequently, several com-
pounds that were previously discovered as inhibitors of 
dengue and West Nile virus proteases have also been re-
ported to inhibit ZIKVpro or even human serine prote-
ases.7 The completely new structural motifs of the present 
study thus not only allow an increase in inhibition by non-
competitive interactions but also selective probing of ZIK-
Vpro. 
The most active compound 2 (Ki = 0.44 µM, KD = 0.009 
µM; gZiPro) exhibits multiple non-canonical structural 
features. Half of all backbone nitrogen atoms of peptide 2 
are methylated and it contains four unnatural O-methyl-
tyrosine side chains, representing a chemical complexity 
that would require several optimization cycles under-
pinned by successful structure-activity relationships if 
starting from a canonical peptide library. None of the se-
lected screening hits showed evidence for competitive in-
hibition at the active site of the protease. This bias toward 
the enrichment of sequences that may target exosites ra-
ther than the active site of ZIKVpro suggests that active-
site interactions of macrocycles were of significantly lower 
affinity during the screening (preventing enrichment of 
those sequences). This in turn suggests low druggability of 
the active site of ZIKVpro (and closely related flaviviruses) 
by classical competitive inhibitors. This conclusion is sup-
ported by a previous study that aimed to identify high-af-
finity active site inhibitors in a library of substrate ana-
logues, where interactions with key residues in the active 
site could be established but only an additional covalent 
bond with the catalytic serine residue yielded affinities in 
the nanomolar range (as in cn-716, Figure 2).4, 8 Alterna-
tively, the absence of competitive inhibitors in the present 
work may be related to the deliberate exclusion of arginine 
(to avoid pharmacokinetic liabilities). All flaviviral prote-
ases share the recognition of basic residues (arginine and 
lysine) in the non-prime substrate site with a particular 
preference for arginine in P1 and most peptide-based inhib-
itors address this recognition motif.3, 8, 9, 27-30 By excluding 
arginine from our screening library, we not only avoided 
an amino acid with a potentially negative impact on drug-




Figure 4. Effect of compounds 1 and 2 on the metabolic activ-
ity of Huh-7 cells (% reduction compared to non-treated). The 
dotted lines indicate an 80% cell-viability cut-off. Neither 
compound shows significant cytotoxic effects at concentra-
tions up to 12.5 μM. A: 24 h incubation. B: 48 h incubation. 
 
The two most active compounds from this screening 
campaign, 1 and 2, displayed no cytotoxic effects at con-
centrations up to 12.5 μM after 24 and 48 hours of incuba-
tion with Huh-7 cells (Figure 4). At higher concentrations 
cytotoxic effects became apparent only for compound 2. 
This result underlines the potential of the macrocyclic pep-
tides 1 and 2 as ZIKVpro lead compounds, as they combine 
nanomolar dissociation and inhibition constants with un-
usual (non-competitive) inhibition mechanisms, excellent 
selectivity against human proteases, and low cytotoxicity. 
Our study also demonstrates that display screenings offer 
an excellent way to rapidly generate selective probes and 
tool compounds that can modulate the enzymatic activity 
of the target protein from fully active (5) to highly inhib-
ited (2). Future attempts will focus on further derivatiza-
tions of the identified and validated hits 1 and 2 to allow 
deeper insights into structure-activity relationships and fa-
cilitate in-cell studies and the generation of structural data 
by X-ray crystallography and NMR spectroscopy. These 
studies will capitalize on chemical opportunities provided 
by the exocyclic C-termini of these compounds that can 
readily be tagged with reporter molecules or moieties that 
modulate solubility or cellular uptake without altering the 
macrocyclic peptide structure.  
In conclusion, we present the first macrocyclic peptide 
inhibitors of ZIKVpro identified through a RaPID screen-
ing technique that is orthogonal to conventional high-
throughput approaches. With a single selection screen and 
no further optimizations, we identified unnatural peptides 
of remarkable affinity, inhibitory activity, and target selec-
tivity. Most importantly, our results indicate that non-
competitive inhibitors can be made that are highly active 
and may present excellent options for probes, tools and po-
tential drug candidates in comparison to active-site inhib-
itors that have been unsuccessfully pursued for a very long 
time. Future work will assess whether a combination of 
competitive and non-competitive inhibitors indeed offers 
a superior approach for the development of antiviral 
agents against Zika, dengue and related viral infectious dis-
eases.  
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Preparation of linked Zika virus NS2B-NS3 protease (gZiPro). The construct has been 
described previously.1, 2 Briefly, it includes 48 hydrophilic core residues of NS2B followed by 
a GGGGSGGGG linker, the 170 N-terminal residues of the NS3 protease domain and a C-
terminal His6 tag. The mutations C80S and C143S were introduced to avoid dimerization by 
oxidation. The T7 expression vector pETMCSI3 was transformed into E. coli BL21(DE3) cells, 
which were grown in LB medium at 37 °C until an OD600 value of 0.6 was reached. 
Subsequently, overexpression was induced with IPTG (1 mM), and the cells were incubated at 
room temperature overnight. The cells were pelleted by centrifuging at 5,000 g for 10 minutes 
and lysed by passing through a French Press (SLM Aminco) at 830 bars. The cell lysate was 
centrifuged for 1 h at 34,000 g and the supernatant was loaded onto a 5 mL Co-NTA column 
(GE Healthcare Life Science) pre-equilibrated with buffer A (50 mM Tris-HCl, pH 7.5, 300 
mM NaCl, 10% (v/v) glycerol). The protein was eluted with a linear gradient of buffer A 
supplemented with 300 mM imidazole, fractions were analyzed by 12% SDS-PAGE, and the 
buffer was exchanged to 50 mM phosphate, pH 7.0, and 50 mM NaCl. 
 
Preparation of unlinked Zika virus NS2B-NS3 protease (bZiPro). The construct was 
obtained from Addgene (plasmid #86846) and expressed and purified exactly as described 
previously.4 
 
Synthesis and screening of peptide library. Library construction and screening were 
performed essentially as described previously (Figure S1).5-11 Briefly, DNA templates for the 
construction of mRNA libraries were synthesized by primer extension and PCR using the 
primers shown in Table S2. Cognate mRNAs were generated by T7 polymerase-mediated 
transcription and covalently linked to PEG-puromycin, before translation in reprogrammed in 
vitro translation reactions without Asp, Glu, Met, and Arg and their cognate aminoacyl-tRNA 
synthetases, as previously described.12 Each reaction contained 1.2 µM mRNA-puro, 12.5 µM 
initiator tRNA (tRNAfMet aminoacylated with ClAc-Tyr), and 25 µM of each elongator tRNA 
(an engineered Glu tRNA including an anticodon of choice - EnGluxxx, see Table S2) 
aminoacylated with the specified non-canonical amino acid. In the first round of selection, 
translation was performed at 150 µL scale to produce approximately 1.2 · 1014 molecules. After 
translation, peptide-mRNA conjugates were isolated from the ribosomes by EDTA treatment 
and reverse transcribed using the CGT3an13.R23 primer and RNase H-reverse transcriptase 
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(Promega). Peptide-mRNA conjugate libraries were panned against 200 nM C-terminally His6-
tagged linked Zika virus NS2B-NS3 protease (gZiPro) immobilized on Dynabeads™ (His-tag 
isolation and pulldown - Thermo Fisher) at 4 °C for 30 min, the beads were washed three times 
with cold PBS-T (10 mM phosphate, pH 7.4, 130 mM NaCl, 0.05% (v/v) Tween-20), and 
cDNA was recovered by PCR using the primers T7g10m.F46 and CGT3an13.R23 prior to T7 
transcription to generate the mRNA for a second round of selection. In the second and later 
rounds of selection, translation was performed at 5 µL scale and libraries were subjected to 6 
rounds of counter selection against uncoated beads prior to panning against linked Zika virus 
NS2B-NS3 protease (gZiPro). Assessment of recovery following each round was performed by 
quantitative real time PCR using Sybr Green I dye (Lonza Japan Ltd) on a light cycler 
nanothermal cycler (Roche). DNA from each round was sequenced using a MiSeq high-
throughput sequencer (Illumina) and analyzed using CLC workbench software (Qiagen) as 
previously described.9 Following alignment of the 100 most enriched sequences (Figure S2), 
peptide families were defined as groups of close analogues for which at least 2 sequences were 
identified, and the most abundant peptide from each was chosen for solid phase synthesis and 
further characterisation. 
 
Solid phase peptide synthesis. Macrocyclic peptides were synthesized at 25 µmol scale using 
standard Fmoc solid phase peptide synthesis methodology using HBTU, HOBt, 
diisopropylethylamine (DIPEA), Rink amide resin, and a Syro I automated synthesizer 
(Biotage). All amino acids and coupling reagents were purchased from Watanabe Chemical 
Ltd, except for DIPEA (Wako Japan). For synthesis of N-methyl-O-methyl-tyrosine residues, 
O-methyl-tyrosine coupling was followed by Fmoc deprotection, nosyl protection of the 
resulting free amine, and on-resin methylation using dimethyl sulfate as follows: following 
Fmoc deprotection, 2-nitrobenzenesulfonyl chloride (22 mg, 0.1 mmol) in N-methyl-2-
pyrrolidone (NMP) and 2,4,6-trimethylpyridine (33 µL, 0.25 mmol) were added to the resin, 
the reaction was allowed to proceed for 15 min at room temperature, and the resin was washed 
(five times) with NMP. Methylation was performed twice using 1,8-diazabicyclo(5.4.0)undec-
7-ene (11.25 µL, 0.075 mmol) and dimethyl sulfate (22.25 µL, 0.25 mmol) in NMP for 5 
minutes, after which the resin was washed (five times) with NMP. Nosyl deprotection was 
performed twice using 1,8-diazabicyclo(5.4.0)undec-7-ene (18.75 µL, 0.125 mmol) and 2-
mercaptoethanol (17.5 µL, 0.25 mmol) in NMP for 5 minutes, after which the resin was washed 
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(five times) with NMP and solid phase peptide synthesis was continued. Identity and purity of 




Zika virus NS2B-NS3 protease enzymatic inhibition assay. All measurements were 
performed in triplicate in 10 mM Tris-HCl, pH 8.5, 20% (v/v) glycerol, and 1 mM CHAPS as 
described previously.13, 14 Different concentrations (ranging from 0 to 100 μM) of compounds 
1-6 (10 mM DMSO stocks) were pipetted into a 96-well plate (black U-bottom, Greiner, Bio-
One). Zika virus NS2B-NS3 protease was added to a final concentration of 1 nM (gZiPro) or 
0.5 nM (bZiPro) and the mixture was incubated for 10 min. Subsequently, the enzymatic 
reaction was initiated by adding the substrate Bz-Nle-Lys-Lys-Arg-AMC (Biosyntan) to four 
final concentrations (15, 30, 45, 60 μM). The gradual release of fluorescent 7-amino-4-
methylcoumarin (AMC) was monitored for 3 min at 460 nm with excitation at 360 nm, using a 
fluorophotometer (Spectramax M2e plate reader, Molecular Devices). Initial velocities were 
derived from the linear curves as variation of relative fluorescence intensity per unit time. The 
relative fluorescence units were converted to the amount of cleaved substrate via a calibration 
curve as described previously.14 IC50 values were calculated from at least seven different 
inhibitor concentrations using Prism 7.0 (Graphpad Software). Ki values for a non-competitive 
inhibition model were calculated using Prism 7.0 (GraphPad Software) using non-linear least-
squares fits. 
 
Surface plasmon resonance (SPR) determination of binding kinetics. Binding kinetics of 
each macrocyclic peptide toward Zika virus NS2B-NS3 protease were determined using a 
Biacore T200 SPR instrument (GE Healthcare Life Sciences). Target protein was immobilized 
on a CM5 chip using EDC/NHS chemistry (Amine Coupling Kit, GE Healthcare Life Sciences) 
to a signal level of ~2000 RU. Binding kinetics were assessed by injection of varying 
concentrations of compounds 1-6 dissolved in 10 mM HEPES, pH 7.4, 150 mM NaCl, 0.5% 
(v/v) polysorbate 20, 0.1% (v/v) DMSO with target regeneration using 10 mM glycine buffer, 
pH 1.5. 
 
Preparation of dengue and West Nile virus NS2B-NS3 proteases. The protease constructs 
of dengue serotype 2 and West Nile virus were described previously.15, 16 In both constructs the 
core sequence of NS2B is covalently ligated to the protease NS3 domain by a GGGGSGGGG 
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linker. Transformation of the pET28a plasmids (Novagen), expression of the His6-tagged 
proteins in E. coli BL21(DE3) cells, and purification by nickel affinity chromatography were 
performed following a previously described protocol.15, 16  
 
 
Dengue and West Nile virus NS2B-NS3 protease enzymatic inhibition assays. All 
measurements were performed in triplicate as described previously.15, 16 Briefly, continuous 
assays were performed in 50 mM Tris-HCl, pH 9, 10% (v/v) ethylene glycol, and 0.0016% Brij 
58 using a BMG Labtech Fluostar OPTIMA microtiter fluorescence plate reader and black 96 
well V-bottom plates (Greiner Bio-One, Germany) with an excitation wavelength of 320 nm 
and a monitored emission wavelength of 405 nm. Compounds 1-6 (10 mM in DMSO) were 
incubated with the dengue virus protease (100 nM) or West Nile virus protease (150 nM) for 
15 min before the enzymatic reaction was initiated by addition of the FRET substrates (final 
concentration 50 μM) Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr (dengue virus protease) or Abz-
Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr (West Nile virus protease). The enzymatic activity was 
monitored for 15 min and initial velocities were derived from the linear curves as variation of 
relative fluorescence intensity per unit time. IC50 values were calculated from at least seven 
different inhibitor concentrations using Prism 7.0 (Graphpad Software). 
 
Thrombin and trypsin enzymatic assays. All measurements were performed in triplicate as 
described previously.16 Briefly, black 96 well V-bottom plates (Greiner Bio-One), a BMG 
Labtech Fluostar OPTIMA microtiter fluorescence plate reader operating at an excitation 
wavelength of 355 nm and an emission wavelength of 460 nm, and a buffer consisting of 50 
mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.05% Tween 20 were used. Compounds 1 and 2 
were preincubated with thrombin (10 nM) or trypsin (1 nM) for 15 minutes at final 
concentrations of 25 and 50 μM, respectively. The cleavage reaction was initiated by addition 
of the Boc-Val-Pro-Arg-AMC substrate (Bachem, Switzerland) at a final concentration of 50 
μM. The activities of thrombin and trypsin were determined as fluorescence increase (RFU/s) 
and monitored for 10 min.  
 
Huh-7 metabolic activity assay. Huh-7 cells were seeded into 96-well cell culture plates at a 
density of 104 cells per well in a final volume of 100 µl. Treatment with compounds 1 and 2 
was performed immediately after seeding at a starting concentration of 50 µM and a 2-fold 
serial dilution. After incubation for 24 h or 48h at 37 °C, the medium was replaced by fresh 
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DMEM and cell viability was measured by adding 20 µl per well CellTiter-Blue® reagent 
(Promega), which monitors the metabolic conversion of resazurin (λmax = 605 nm) to resorufin 
(λmax = 573 nm). Subsequently, cells were incubated for 1 h at 37 °C and the absorbance was 
measured at 600 and 570 nm. For evaluation the difference in absorbance values (absolute 
values or relative to the non-treated control) were plotted against the compound concentration.  
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Figure S1. Schematic illustration of RaPID screening process. 1. A DNA library assembled 
from synthetic oligonucleotides is transcribed into RNA (blue) and ligated to puromycin at the 
3’ end. 2. This library is translated in a genetically reprogrammed reaction, resulting in a 
macrocyclic peptide library in which each peptide is covalently linked to its cognate mRNA. 
This is then reverse transcribed to generate peptide-RNA:DNA molecules. 3. Counter 
selections are used to remove peptides that bind non-specifically to the bead surface. 4. The 
library is then panned against Zika virus NS2B-NS3 protease immobilised on magnetic beads. 
5. An enriched DNA library is then recovered by PCR and the process is repeated until 
increased rates of target binding are observed. Deconvolution of the library can be achieved 
through sequencing of the final (and intermediate) enriched DNA libraries. 
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Figure S2. Alignment of peptide 
sequences identified following 
selection for Zika virus NS2B-NS3 
ligands. The hundred most frequent 
peptides from each library are shown. 
Sequences from the ClAc-L-tyrosine 
initiated library are shown in the left-
hand column, and sequences from the 
ClAc-D-tyrosine initiated library are 
shown in the right-hand column. Other 
non-canonical amino acids are 
represented as indicated in the legend. 
Percentage values next to each sequence 
indicate overall prevalence in the 
enriched library. Black brackets show 
the breakdown of the identified 
sequences into 6 families (5 ClAc-L-
tyrosine initiated and 1 ClAc-D-tyrosine 
initiated). Red arrows indicate 
sequences chosen for synthesis and 
further characterization, with numbers 
corresponding to the compounds listed 




Figure S3. MALDI-TOF MS analysis of synthesized peptides. 
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Figure S4. Zika virus NS2B-NS3 protease binding kinetics of compounds 1-6. Single-cycle 
kinetics experiments were performed using surface immobilized Zika virus NS2B-NS3 
protease (gZiPro) with varying concentrations of macrocyclic peptide analyte. Compounds 
were analysed at the concentrations indicated. Kinetic parameters (see Table S1) were 
determined by fitting a 1:1 binding model, with the exception of compound 6 which was fitted 
using a two-state binding model. In each case, the red line indicates the data trace, and the 
black line indicates the fitted curve. 
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Figure S5. Dose response curves of Zika virus NS2B-NS3 protease inhibitors. 
Measurements were performed in triplicate at concentrations of 15 μM substrate and 1 nM 
linked Zika virus NS2B-NS3 protease (gZiPro). Dose-response curves were fitted using a 
sigmoid fitting function. Similar dose-response curves were recorded for at least three 




Figure S6. Dose response curves of Zika virus NS2B-NS3 protease inhibitors. 
Measurements were performed in triplicate at concentrations of 15 μM substrate and 0.5 nM 
unlinked Zika virus NS2B-NS3 protease (bZiPro). Dose-response curves were fitted using a 





Figure S7. Absorbance data of Huh-7 cell viability assay for compounds 1 and 2.  Cell 
viability was determined using CellTiter-Blue® reagent (Promega). The difference in 
absorbance at 570 nm and 600 nm is plotted against the compound concentration used for 









Table S1. Kinetic parameters for Zika virus NS2B-NS3 protease binding of compounds 
identified. 
Compound kon (M-1 · s-1) koff (s-1) KD (nM) 
1 1.47 x 105 0.003 20 
2 2.22 x 105 0.002 8.7 
3 3.54 x 105 0.003 7.5 
4 1.83 x 105 0.002 8.9 
5 3.22 x 105 0.002 5.0 
6* 
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* Data of compound 6 were fitted using a two-state binding model. Therefore, two values are 
reported for kon and koff. 
Table S2. DNA oligonucleotides used in this work. 


































Table S3. Non-linear least-squares fitting parameters for gZiPro (Graphpad Prism 7.0). 
Compound Non-competitive modela  Competitive modelb Mixed modelc 
 Ki  
(95% CI)d 
R2 Ki  
(95% CI)d 







(0.68 – 0.96) 
0.943 










(0.39 – 0.50) 
0.963 










(1.65 – 2.43) 
0.921 










(16.9 – 24.9) 
0.913 










(2.92 – 4.24) 
0.934 









a Fitted using  𝑣𝑣𝑚𝑚𝑚𝑚𝑚𝑚
𝑚𝑚𝑎𝑎𝑎𝑎 =  𝑣𝑣𝑚𝑚𝑚𝑚𝑚𝑚
1+[𝐼𝐼]𝐾𝐾𝑖𝑖
 
b Fitted using  𝐾𝐾𝑚𝑚




c Fitted using  𝑣𝑣𝑚𝑚𝑚𝑚𝑚𝑚
𝑚𝑚𝑎𝑎𝑎𝑎 =  𝑣𝑣𝑚𝑚𝑚𝑚𝑚𝑚
1+ [𝐼𝐼]𝛼𝛼𝐾𝐾𝑖𝑖
    ,   𝐾𝐾𝑚𝑚




d Values for the 95% confidence interval are shown in parenthesis. 
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